| Heart disease and stroke statistics—2017 update: a report from the American Heart Association EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ... circulation 135 (10), e146-e603, 2017 | 26579 | 2017 |
| Discovery and refinement of loci associated with lipid levels CJ Willer, EM Schmidt, S Sengupta, GM Peloso, S Gustafsson, S Kanoni, ... Nature genetics 45 (11), 1274, 2013 | 3075* | 2013 |
| Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women S Bansal, JE Buring, N Rifai, S Mora, FM Sacks, PM Ridker Jama 298 (3), 309-316, 2007 | 2183 | 2007 |
| Vitamin D supplements and prevention of cancer and cardiovascular disease JAE Manson, NR Cook, IM Lee, W Christen, SS Bassuk, S Mora, ... New England Journal of Medicine 380 (1), 33-44, 2019 | 1726 | 2019 |
| Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms S Mora, N Cook, JE Buring, PM Ridker, IM Lee Circulation 116 (19), 2110-2118, 2007 | 1389 | 2007 |
| Common variants associated with plasma triglycerides and risk for coronary artery disease R Do, CJ Willer, EM Schmidt, S Sengupta, C Gao, GM Peloso, ... Nature genetics 45 (11), 1345-1352, 2013 | 1063 | 2013 |
| Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis SM Boekholdt, BJ Arsenault, S Mora, TR Pedersen, JC LaRosa, PJ Nestel, ... Jama 307 (12), 1302-1309, 2012 | 1045 | 2012 |
| Marine n− 3 fatty acids and prevention of cardiovascular disease and cancer JAE Manson, NR Cook, IM Lee, W Christen, SS Bassuk, S Mora, ... New England Journal of Medicine 380 (1), 23-32, 2019 | 1033 | 2019 |
| Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint … BG Nordestgaard, A Langsted, S Mora, G Kolovou, H Baum, E Bruckert, ... European heart journal 37 (25), 1944-1958, 2016 | 910 | 2016 |
| Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials SM Boekholdt, GK Hovingh, S Mora, BJ Arsenault, P Amarenco, ... Journal of the American College of Cardiology 64 (5), 485-494, 2014 | 847 | 2014 |
| Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study S Mora, RF Redberg, Y Cui, MK Whiteman, JA Flaws, AR Sharrett, ... Jama 290 (12), 1600-1607, 2003 | 795 | 2003 |
| Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women S Mora, JD Otvos, N Rifai, RS Rosenson, JE Buring, PM Ridker Circulation 119 (7), 931-939, 2009 | 755* | 2009 |
| Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children TO Kilpeläinen, L Qi, S Brage, SJ Sharp, E Sonestedt, E Demerath, ... PLoS medicine 8 (11), e1001116, 2011 | 745 | 2011 |
| Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement F Kronenberg, S Mora, ESG Stroes, BA Ference, BJ Arsenault, L Berglund, ... European heart journal 43 (39), 3925-3946, 2022 | 689 | 2022 |
| LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA) S Mora, M Szklo, JD Otvos, P Greenland, BM Psaty, DC Goff Jr, ... Atherosclerosis 192 (1), 211-217, 2007 | 623 | 2007 |
| Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease P Zanoni, SA Khetarpal, DB Larach, WF Hancock-Cerutti, JS Millar, ... Science 351 (6278), 1166-1171, 2016 | 594 | 2016 |
| Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women S Mora, IM Lee, JE Buring, PM Ridker Jama 295 (12), 1412-1419, 2006 | 585 | 2006 |
| Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events S Mora, N Rifai, JE Buring, PM Ridker Circulation 118 (10), 993-1001, 2008 | 544 | 2008 |
| Baseline and on-statin treatment lipoprotein (a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials P Willeit, PM Ridker, PJ Nestel, J Simes, AM Tonkin, TR Pedersen, ... The Lancet 392 (10155), 1311-1320, 2018 | 517 | 2018 |
| Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an … AV Khera, BM Everett, MP Caulfield, FM Hantash, J Wohlgemuth, ... Circulation 129 (6), 635-642, 2014 | 507 | 2014 |
